The publication of the World Health Organization’s (WHO) first “Global Status Report on Rehabilitation” has been effectively paused after the Executive Board concluded that the proposed methodology for measuring progress failed to capture the complex realities of health systems, particularly those in conflict zones. In a politically charged debate on Thursday, member states argued that […] Continue reading ->
A stark debate over who owns the data in the future of AI and digital health emerged at the World Health Organization (WHO) Executive Board on Wednesday. Low and middle-income countries warned that the rapid deployment of new technologies risks accelerating data extraction and increasing inequality, cautioning that – without strict AI governance, sustainable financing […] Continue reading ->
A dispute over technology transfer rights pushed the World Health Organization (WHO) to delay its Global Action Plan on Antimicrobial Resistance (AMR) for further informal talks. Instead, the Executive Board approved a compromise drafted by Nepal and Ethiopia on Wednesday to reopen negotiations on intellectual property, specifically regarding “voluntary and mutually agreed technology transfers.” This […] Continue reading ->
The World Health Organization (WHO) is set for a massive shift in global health priorities with a new emergency care strategy, moving away from isolated hospital “silos” toward a seamless continuum of care. On Tuesday, the Executive Board unanimously adopted a 10-year strategy (2026 to 2035) for Integrated Emergency, Critical, and Operative Care (ECO), positioning […] Continue reading ->
STRASBOURG – The European Parliament backed the EU’s Critical Medicines Act (CMA) on Tuesday in a decisive move to secure Europe’s pharmaceutical supply chains from geopolitical shocks. With an overwhelming majority of 503 votes in favour, 57 against, and 108 abstentions, MEPs endorsed a sweeping industrial policy designed to re-shore the production of active ingredients […] Continue reading ->
The European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) have jointly established new AI principles in drug development to reduce regulatory divergence between the major markets of the European Union and the United States. Industry associations have applauded the landmark accord, as it strengthens harmonisation across the regions – but emphasise […] Continue reading ->